Aptevo Therapeutics Inc News Releases http://ir.aptevotherapeutics.com/ Aptevo Therapeutics Inc News Releases en Aptevo Therapeutics Reports First Quarter 2019 Financial Results http://ir.aptevotherapeutics.com/news-releases/news-release-details/aptevo-therapeutics-reports-first-quarter-2019-financial-results Achieves 73% Increase in First Quarter 2019 Year-Over-Year IXINITY® Net Revenue On Target for Launch of New 3,000 IU IXINITY Assay Mid-2019 Advances Enrollment in APVO436 and APVO210 Phase 1 Clinical Studies; Anticipates Top-Line Preliminary Data Read-outs in the Third and Fourth Quarters of 2019 Thu, 09 May 2019 09:00:00 -0400 Aptevo Therapeutics Inc News Releases 7941 Aptevo Therapeutics Reports IXINITY® and Pipeline Progress http://ir.aptevotherapeutics.com/news-releases/news-release-details/aptevo-therapeutics-reports-ixinityr-and-pipeline-progress Reports 73% Increase in IXINITY Year-Over-Year Quarterly Net Revenue in Q1 2019 Anticipates Launching New IXINITY 3,000 IU Assay Mid-2019 Advances Dosing in Additional Cohorts in APVO436 and APVO210 Clinical Programs On Schedule to File a CTA for ALG.APV-527 in Q4 2019 SEATTLE , April 15, 2019 Mon, 15 Apr 2019 09:00:00 -0400 Aptevo Therapeutics Inc News Releases 7921 Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting http://ir.aptevotherapeutics.com/news-releases/news-release-details/aptevo-therapeutics-presents-new-preclinical-data-apvo436-and APVO436 Preclinical Data Continue to Show Promising Results Supporting Clinical Development for the Treatment of Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS) and Differentiation from a Competitor Candidate Phase 1/1b Clinical Study of APVO436 Continuing Dose Tue, 02 Apr 2019 09:02:00 -0400 Aptevo Therapeutics Inc News Releases 7886 Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting http://ir.aptevotherapeutics.com/news-releases/news-release-details/aptevo-therapeutics-present-new-preclinical-data-apvo436-and SEATTLE , March 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that preclinical data for two of its ADAPTIR™ bispecific antibody candidates will be presented Mon, 25 Mar 2019 09:02:00 -0400 Aptevo Therapeutics Inc News Releases 7866 Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases http://ir.aptevotherapeutics.com/news-releases/news-release-details/aptevo-therapeutics-begins-phase-1-clinical-trial-apvo210-novel Unique Mechanism of Action Suppresses Inflammation and Immune Activation  Without Promoting Pro-Inflammatory Lymphocyte Stimulation Preliminary Phase 1 Data Read-outs Anticipated Q3 and Q4 2019 SEATTLE , March 20, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. Wed, 20 Mar 2019 09:02:00 -0400 Aptevo Therapeutics Inc News Releases 7846 Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update http://ir.aptevotherapeutics.com/news-releases/news-release-details/aptevo-therapeutics-reports-2018-financial-results-and-provides Achieves Record Annual IXINITY ® Net Revenue of $23.1 Million  Representing 111% Increase Over 2017 Advances APVO436 Into Phase 1/1b Clinical Trial for Treatment of  Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome Receives Authorization to Commence Dosing in Phase 1 Clinical Trial of Mon, 18 Mar 2019 09:00:00 -0400 Aptevo Therapeutics Inc News Releases 7826 Aptevo Announces Pricing of $22 Million Offering of Common Stock and Warrants http://ir.aptevotherapeutics.com/news-releases/news-release-details/aptevo-announces-pricing-22-million-offering-common-stock-and SEATTLE , March 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced the pricing of (i) for a combined public offering price of $1.00 per share of common stock and Thu, 07 Mar 2019 09:13:00 -0500 Aptevo Therapeutics Inc News Releases 7806 Aptevo Announces Proposed Public Offering of Common Stock and Warrants http://ir.aptevotherapeutics.com/news-releases/news-release-details/aptevo-announces-proposed-public-offering-common-stock-and SEATTLE , March 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common Wed, 06 Mar 2019 16:37:00 -0500 Aptevo Therapeutics Inc News Releases 7796 Aptevo Therapeutics Highlights Key 2019 Priorities http://ir.aptevotherapeutics.com/news-releases/news-release-details/aptevo-therapeutics-highlights-key-2019-priorities ADAPTIR™ Bispecific Antibody Candidates Poised to Progress in Clinical Development APVO436 Advancing in Phase 1 Clinical Trial for Acute Myeloid Leukemia; APVO210 Beginning Phase 1 Clinical Trial in Q1 2019; ALG.APV-527 Progressing with CTA Submission in H2 2019 Projecting 1/3 Cash Burn Reduction Mon, 07 Jan 2019 08:30:00 -0500 Aptevo Therapeutics Inc News Releases 7701 Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics http://ir.aptevotherapeutics.com/news-releases/news-release-details/aptevo-therapeutics-collects-33-million-escrow-funds-saol SEATTLE , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has collected $3.3 million in escrow funds from Saol Therapeutics related to a purchase agreement Thu, 03 Jan 2019 09:02:00 -0500 Aptevo Therapeutics Inc News Releases 7691